August 29, 2026

Medicare News Weekly Recap: August 24–28, 2026

It was another busy week for Medicare.

But this week’s headlines weren’t primarily about new 2027 plan benefits.

Instead, they raised bigger questions about:

What Medicare is paying for.

Whether additional Medicare Advantage spending translates into better outcomes.

How aggressively the federal government should fight healthcare fraud.

How Medicare is approaching GLP-1 medications.

And:

Who will be able to supply certain medical equipment as Medicare prepares for its next competitive bidding round.

For beneficiaries, there is a common thread running through these stories:

More benefits, more spending or a higher-rated program doesn’t automatically mean better personal healthcare.

Let’s break down the five Medicare developments worth knowing from the week of August 24–28, 2026.

This Week in Medicare — At a Glance

Date	Medicare Development	Why It Matters
Aug. 24	Study compares diabetes outcomes in Medicare Advantage and Traditional Medicare	Raises questions about whether supplemental benefits translate into measurable chronic-care improvements
Aug. 25	MedPAC’s $76 billion MA spending estimate returns to focus	Highlights ongoing debate over how Medicare pays private plans
Aug. 26	CMS gains exclusion authority	Could strengthen federal enforcement against bad actors
Aug. 27	Medicare GLP-1 Bridge program expands access	Eligible beneficiaries can access certain GLP-1 treatment at a predictable copay
Aug. 28	DMEPOS enrollment moratorium expires	Suppliers can again submit initial Medicare enrollment applications as Round 2028 approaches

Let’s take them one at a time.

Monday: Medicare Advantage Extras Don’t Necessarily Mean Better Diabetes Outcomes

One of the week’s most interesting Medicare stories involved something beneficiaries rarely see discussed in advertisements:

Health outcomes.

A study highlighted by MarketWatch examined older adults with Type 2 diabetes enrolled in Medicare Advantage compared with those in Traditional Medicare.

The observational study followed roughly 35,000 older adults for about 3.5 years.

Its central finding was striking:

Researchers did not find significant improvements among Medicare Advantage beneficiaries in major diabetes-related measures such as:

- A1C

- LDL cholesterol

- Blood pressure

compared with beneficiaries in Traditional Medicare.

That’s particularly interesting because Medicare Advantage plans frequently offer supplemental benefits designed, at least in part, to support healthier living.

Those can include:

- Fitness programs

- Transportation

- Food-related benefits for eligible members

- OTC benefits

- Care-management programs

- Other supplemental services

But the study suggests we shouldn’t automatically assume that having more supplemental benefits produces better measurable chronic-disease outcomes.

What This Does NOT Mean

This finding should not be interpreted as:

“Medicare Advantage is bad for people with diabetes.”

Nor does it establish:

“Original Medicare provides better diabetes care.”

The study was observational.

Instead, it raises a more useful question:

Are beneficiaries actually receiving and using the services most likely to improve their health?

That is a very different conversation from simply asking:

“Which plan gives me the biggest grocery allowance?”

Core Coverage vs. Extra Benefits

This reinforces something we’ve been emphasizing in our recent Medicare guides.

When comparing Medicare Advantage plans, start with:

Look Here First	Look Here Second
Doctors	Dental
Specialists	Vision
Hospitals	Hearing
Prescriptions	OTC
Medical costs	Fitness
MOOP	Transportation
Plan rules	Eligible food/grocery benefits

Extras can matter.

But they shouldn’t distract from whether the underlying healthcare coverage fits you.

Our guide to Medicare Advantage Extra Benefits for 2027 explains this approach in greater detail.

Monday’s takeaway:

Benefits you can use matter more than benefits that simply look good in an advertisement.

Tuesday: Medicare Advantage’s $76 Billion Spending Debate

Tuesday’s Medicare conversation turned from healthcare outcomes to healthcare spending.

According to the Medicare Payment Advisory Commission—MedPAC—Medicare is projected to spend approximately:

$76 billion more on Medicare Advantage in 2026

than Medicare would be expected to spend if those beneficiaries were enrolled in fee-for-service Traditional Medicare.

That represents approximately 14% higher payments, according to MedPAC’s 2026 analysis.

This isn’t merely an estimate circulating among advocacy organizations.

MedPAC is an independent congressional agency that advises Congress on Medicare policy.

Where Does the $76 Billion Difference Come From?

The Medicare Advantage payment system is complicated.

Two major factors identified in the policy debate are:

Favorable selection

Differences between the expected healthcare spending of people who enroll in Medicare Advantage and comparable beneficiaries remaining in Traditional Medicare.

Coding intensity

Medicare Advantage plans have financial incentives to document beneficiaries’ diagnoses because payments are adjusted based partly on health status.

KFF notes that differences in coding practices can make Medicare Advantage beneficiaries appear sicker for payment purposes than comparable beneficiaries under Traditional Medicare.

MedPAC estimates the combined result contributes significantly to the difference between Medicare Advantage payments and expected Traditional Medicare spending.

$76 Billion in Perspective

2026 Medicare Advantage Metric	Estimate
MA payment difference vs. FFS Medicare	$76 billion
Payment difference per enrollee	~14% higher
Average rebate per beneficiary	~$2,660/year

Medicare Advantage rebates are important because plans can use them to fund things such as:

- Lower cost-sharing

- Supplemental benefits

- Reduced premiums

- Other plan benefits

KFF estimates those rebates average about $2,660 per Medicare Advantage enrollee in 2026.

Does This Mean Medicare Advantage Plans Receive $2,660 in Cash for Every Member to Spend?

No.

That’s an important distinction.

The rebate isn’t a personal cash payment to the beneficiary.

It’s part of the Medicare Advantage payment system and can help finance benefits and reduced member costs.

This is another reason advertisements about:

“money back”

or:

“extra benefits”

shouldn’t be confused with the mechanics of Medicare’s payments to insurers.

Why Beneficiaries Should Care

The Medicare Advantage payment debate isn’t simply an argument between Washington policymakers and insurance companies.

Medicare spending ultimately affects:

- Federal Medicare expenditures

- Taxpayers

- Medicare financing

- Beneficiary premiums

- Future payment policy

- The resources available for Medicare benefits

KFF reports that Medicare Advantage spending reached $534 billion in 2025, representing more than half of Medicare Part A and Part B program spending.

At the same time, Medicare Advantage provides benefits many beneficiaries value.

That’s what makes the policy debate complicated.

Don’t Turn a National Funding Debate Into a Personal Plan Decision

This is important.

The $76 billion figure doesn’t mean:

“Don’t enroll in Medicare Advantage.”

Your personal decision still depends on:

- Doctors

- Hospitals

- Prescriptions

- Premium

- Copays

- MOOP

- Network

- Plan type

- Benefits

- Your healthcare needs

Use our Compare Medicare Plans resources to understand those differences.

Tuesday’s takeaway:

Medicare Advantage’s value to an individual beneficiary and its cost to the Medicare program are two different questions.

Both deserve scrutiny.

Wednesday: CMS Gets a New Weapon Against Medicare Fraud

Wednesday brought an important Medicare enforcement development.

Historically, the HHS Office of Inspector General has held exclusion authority under federal law.

An exclusion can prevent an individual or organization from receiving federal healthcare-program payment for services they provide, order or prescribe.

The OIG maintains the federal List of Excluded Individuals/Entities, or LEIE.

But HHS has now announced a significant enforcement shift:

CMS is being given authority to exercise healthcare-program exclusions alongside OIG.

Healthcare law firm Holland & Knight described the development as potentially expanding the government’s ability to pursue exclusion actions.

Why Exclusion Is Such a Serious Enforcement Tool

Imagine a healthcare provider commits serious Medicare fraud.

A normal monetary penalty hurts.

But exclusion can be much more consequential.

If excluded, federal healthcare programs generally cannot pay for services furnished, ordered or prescribed by that person or entity.

That can effectively prevent certain healthcare businesses from participating in:

- Medicare

- Medicaid

- Other federally funded healthcare programs

depending on the circumstances.

What CMS Can Already Do

CMS isn’t new to Medicare fraud enforcement.

It already possesses tools involving:

- Provider enrollment

- Payment suspension

- Enrollment revocation

- Program-integrity screening

- Claims oversight

What changes here is the potential addition of exclusion authority.

However, an important caveat remains:

The details aren’t fully settled yet.

Holland & Knight notes that details concerning how CMS and OIG will divide responsibilities have not yet been publicly released.

So I would not describe the change as eliminating the OIG or prosecution process.

Instead:

CMS may now have another significant enforcement tool alongside the existing federal framework.

Why Medicare Beneficiaries Should Care

Medicare fraud isn’t victimless.

Fraudulent billing can:

- Waste Medicare funds

- Expose beneficiaries to unnecessary services

- Create false medical records

- Compromise Medicare numbers

- Increase program costs

It also connects to another issue we’ve been covering:

Medicare scams.

Never provide your Medicare number or sensitive information to an unexpected caller simply because they claim to represent Medicare.

Wednesday’s takeaway:

CMS appears positioned to play a more direct role in excluding bad actors from federal healthcare programs—but watch for additional federal guidance explaining how the new authority will work.

Thursday: Medicare’s GLP-1 Bridge Program Is Expanding Access

Few drug classes have generated as much attention recently as:

GLP-1 medications.

These medications have become major treatments in areas involving:

- Diabetes

- Obesity

- Cardiovascular risk

And Medicare’s coverage landscape is evolving.

One important development this summer is the:

Medicare GLP-1 Bridge program.

Walgreens says the nationwide CMS initiative began July 1 and allows qualifying Medicare beneficiaries to access FDA-approved GLP-1 medications for weight management at a predictable:

$50 monthly copay.

Walgreens has also said pharmacists at nearly 8,000 locations are helping eligible Medicare patients navigate the program.

Important: Not Every Medicare Beneficiary Automatically Qualifies

This needs to be prominent because GLP-1 headlines can easily create confusion.

The Bridge program does not mean:

“Everyone on Medicare can get Wegovy for $50.”

Eligibility requirements apply.

Beneficiaries should speak with their healthcare provider and verify whether they meet the program requirements and whether a particular medication is appropriate for them.

Why Medicare GLP-1 Coverage Has Been Complicated

Historically, Medicare Part D has had statutory restrictions involving drugs used for weight loss.

But some GLP-1 medications can also have FDA-approved indications beyond weight reduction.

That has created a rapidly evolving Medicare coverage landscape.

The Bridge program represents another step toward expanding access for qualifying beneficiaries.

What Should Beneficiaries Do?

If you’re interested in a GLP-1 medication:

1. Talk with your physician.

Determine whether the medication is medically appropriate.

2. Determine whether you meet Medicare’s eligibility requirements.

Don’t rely on an advertisement.

3. Check your current coverage.

Your plan and indication matter.

4. Review your 2027 prescription coverage.

Formularies and coverage rules can change.

5. Record the medication on your prescription list.

Our Medicare Prescription List for Plan Comparison explains how to prepare your medications before comparing coverage.

Thursday’s takeaway:

The $50 Bridge pathway could make GLP-1 treatment substantially more accessible for qualifying Medicare beneficiaries—but eligibility and clinical appropriateness still matter.

Friday: Medicare Reopens Enrollment for DMEPOS Suppliers

Friday’s story sounds technical.

But it could eventually affect beneficiaries who rely on certain medical equipment and supplies.

DMEPOS stands for:

Durable Medical Equipment, Prosthetics, Orthotics and Supplies.

CMS had placed a nationwide temporary moratorium on initial enrollment applications from certain medical-supply companies beginning:

February 27, 2026.

The moratorium lasted six months.

On:

August 27, 2026

the temporary moratorium expired.

CMS’s Competitive Bidding Implementation Contractor confirmed that Medicare enrollment contractors are again accepting initial DMEPOS supplier applications.

Why Did Medicare Stop New Supplier Enrollment?

The temporary moratorium was part of CMS’s program-integrity strategy.

Medicare equipment and medical-supply billing has historically been an area vulnerable to:

- Fraud

- Improper billing

- Phantom suppliers

- Medically unnecessary equipment

- Beneficiary scams

Temporarily restricting enrollment gave CMS another mechanism to scrutinize new supplier participation.

Now that the moratorium has expired, qualifying suppliers can once again apply.

Why Round 2028 Matters

The reopening also matters because CMS is preparing for the next:

DMEPOS Competitive Bidding Program — Round 2028.

CMS says suppliers planning to bid should submit completed enrollment applications promptly so Medicare contractors have enough time to process them before bidding.

The next competitive bidding round includes categories such as:

- Class II continuous glucose monitors and insulin pumps

- Urological supplies

- Ostomy supplies

- Hydrophilic urinary catheters

- Off-the-shelf back braces

- Off-the-shelf knee braces

- Off-the-shelf upper-extremity braces.

That’s more precise than saying the change immediately expands every category of high-tech medical equipment.

The DMEPOS Timeline

Date	Development
Feb. 27, 2026	Temporary supplier enrollment moratorium begins
Aug. 27, 2026	Six-month moratorium expires
Late 2026	Round 2028 bidding preparations continue
2027	Contracts expected to be awarded
By Jan. 1, 2028	Next competitive-bidding round takes effect

CMS says the new competitive bidding program is intended to establish sustainable prices, save money, combat fraud and preserve access to quality items and services.

Friday’s takeaway:

Supplier enrollment reopening is an important step toward Medicare’s 2028 medical-equipment competitive bidding system—not an immediate overhaul of beneficiaries’ DME coverage.

What Connected All Five Medicare Stories This Week?

At first glance, diabetes research, Medicare Advantage payments, fraud enforcement, GLP-1 drugs and medical equipment don’t seem connected.

But they are.

The underlying question is:

Is Medicare spending producing meaningful value for beneficiaries?

Consider the week:

Monday: Are supplemental benefits translating into better chronic-care outcomes?

Tuesday: Is Medicare paying Medicare Advantage plans appropriately?

Wednesday: Can Medicare remove bad actors more effectively?

Thursday: Can innovative drugs become more accessible without making coverage unsustainable?

Friday: Can Medicare preserve access to medical equipment while controlling costs and fraud?

Different stories.

Same policy challenge:

Better healthcare, responsible spending and meaningful beneficiary access.

What Medicare Beneficiaries Should Do Right Now

You don’t need to become a Medicare policy expert because of these headlines.

But heading toward 2027 Open Enrollment, they reinforce five practical actions:

1. Evaluate core healthcare before supplemental perks. Doctors, hospitals, prescriptions and costs should come before grocery cards or gym memberships.

1. Don’t assume one Medicare coverage type is universally better. Compare your individual circumstances.

1. Protect your Medicare information. Federal fraud enforcement is increasing for a reason.

1. Review expensive prescriptions carefully. New programs can change access, but eligibility and plan rules matter.

1. Review your 2027 coverage even if you’re happy today. Benefits, formularies, costs, networks and plan rules can change.

Our Medicare Open Enrollment resources can help you prepare before October 15.

And if you’re beginning from scratch, visit our Compare Medicare Plans hub.

Preparing for Medicare Open Enrollment?

Medicare headlines can be useful.

But national headlines don’t tell you:

whether your doctor participates.

whether your prescriptions are covered.

what your hospital costs could be.

or which available coverage fits your needs.

That’s where an individual Medicare review becomes important.

Call Medicare Plan Assistance at (561) 808-9410

We can help you understand your current Medicare coverage and what you should review as 2027 plan information becomes available.

Medicare news tells you what’s changing nationally. Your Medicare review tells you what those changes mean for you.

Frequently Asked Questions

Is Medicare Advantage better than Original Medicare for people with diabetes?

A recently reported observational study found no significant improvement in several key diabetes measures among Medicare Advantage beneficiaries compared with those in Traditional Medicare. That doesn’t establish that one coverage type is universally better. Individual provider access, prescriptions, costs and coverage needs still matter.

Is Medicare really spending $76 billion more on Medicare Advantage in 2026?

MedPAC estimates that Medicare Advantage payments in 2026 are approximately 14%—or $76 billion—higher than estimated spending if the same beneficiaries were covered under fee-for-service Medicare.

Does that mean Medicare Advantage beneficiaries receive $2,660?

No. The approximately $2,660 figure refers to average annual Medicare Advantage rebates per enrollee in 2026, not a cash payment directly given to every beneficiary. Plans use rebates for supplemental benefits, reduced cost-sharing and other permitted purposes.

Does CMS now have authority to exclude providers from Medicare?

HHS has announced a move allowing CMS to exercise exclusion authority alongside OIG. However, important details concerning how responsibilities will be divided remain to be released.

Can Medicare beneficiaries get GLP-1 medications for $50 per month?

Certain qualifying Medicare beneficiaries may be able to access eligible GLP-1 medications through the Medicare Bridge program at a $50 monthly copay. Eligibility requirements apply, and beneficiaries should discuss treatment with their healthcare provider.

Did Medicare reopen enrollment for medical-equipment suppliers?

Yes. The six-month temporary moratorium on initial enrollment applications for affected DMEPOS medical-supply companies expired August 27, 2026, and Medicare enrollment contractors are again accepting initial applications.